Study Dampens Hope for GLP-1s as Insulin Off-Ramp in Type 2 Diabetes

A study found that adding a GLP-1 receptor agonist did not reduce the likelihood of veterans with type 2 diabetes discontinuing basal insulin therapy compared to other glucose-lowering agents. The findings suggest GLP-1s may not serve as an effective insulin off-ramp for this population.